🏥 Health Technology Product / Tool Active Founded 2024

ACE-AI

Parent
Synapxe
Lead Ministry
Ministry of Health (MOH)
Scale / KPIs
Planned deployment to 1,400+ clinics nationally by 2027; can serve all 5.8M residents
Last Updated
2026-05-02

ACE-AI is an AI health-screening tool built by Synapxe that predicts diabetes and hyperlipidaemia risk. It is **Singapore's first medical-AI product to receive a true nationwide deployment** — by 2027 it will cover all Healthier SG clinics, in theory benefiting all 5.8 million residents.

📖 What it is

How ACE-AI works:

  • Inputs: routine health data captured at the clinic (age, sex, BMI, blood pressure, lifestyle questionnaire, etc.)
  • Prediction: probability of developing diabetes / hyperlipidaemia in the next 5–10 years
  • Output: clinicians see a risk score plus intervention recommendations
  • Closed loop: high-risk individuals are pulled into the Healthier SG proactive health-management workflow

Technically it is not complex — at its core it is a risk-prediction model trained on national health data. But its deployment scale and real-world medical impact far exceed most academic medical AI.

🤖 Relation to AI

ACE-AI is a representative of the "pragmatic line" in medical AI deployment — not chasing frontier models, but chasing real medical impact.

Its value lies not in algorithmic novelty, but in:

  • Data scale: training uses national NEHR data — a sample size larger than any commercial medical AI
  • Deployment scale: simultaneous use across 1,400+ clinics nationwide
  • Closed-loop value: prediction outputs feed directly into Healthier SG intervention flows, not just "diagnostic assistance"

This kind of "national-grade data + national-grade deployment" medical AI project is rare globally.

🇸🇬 Relation to Singapore

ACE-AI is the flagship "national deployment" project of Singapore's medical AI strategy.

In the "seven transmission levers" framework:

  • Lever 5 (government adoption): a national-scale AI deployment in the healthcare system
  • Lever 3 (industry adoption): a model for medical AI deployment

A take: ACE-AI proves that Singapore's "small country + centralised healthcare system" is a real advantage in medical AI — large countries like the US or Indonesia could not pull off "one nationwide system" even if they wanted to. ACE-AI's success (if it succeeds) will be studied by the global medical AI industry for years.

Worth watching: actual prediction accuracy, clinician adoption (do doctors actually intervene per the AI's recommendation), and improvement in patient outcomes (does incidence among high-risk patients drop) — answers will only become clear in 5–10 years.

🗓️ Key Milestones

  1. 2024
    ACE-AI deployed in pilot clinics
  2. 2027
    Planned nationwide rollout

🔗 Related

Sources

Within 🏥 Health Technology